Journal article
Bronchial segmental heterogeneity of responsiveness to modulator therapy in cystic fibrosis: linking structural improvements on CT to Inflammation in Bronchoalveolar lavage fluid
ERJ open research
09/10/2026
DOI: 10.1183/23120541.00847-2026
Abstract
Background
Although Elexacaftor–tezacaftor–ivacaftor (ETI) improves lung function and reduces exacerbations in cystic fibrosis (CF), airway inflammation and bronchial wall thickening do not completely resolve. Characterizing regional heterogeneity in bronchial wall thickness before and after ETI may provide insight into residual disease. We investigated whether bronchial wall thickening during ETI reflects ongoing inflammation, mucus burden, and infection at the segmental level.
Methods
In this prospective observational cohort study, paired pre-ETI and 1.5-year post-ETI chest CT scans and bronchoalveolar lavage (BAL) samples were analyzed from five preselected lung segments in nine adults with CF. An AI-based pipeline generated automated segmental bronchus–artery metrics, including bronchial wall area (Bwa/Boa), wall thickness (Bwt/A), inner diameter (Bin/A), and outer diameter (Bout/A) ratios, as well as mucus plug number and volume. These metrics were correlated with segment-matched BAL markers of inflammation, mucus burden, and Pseudomonas aeruginosa infection.
Results
Responses to ETI were heterogeneous both between and within subjects. Across 176 segments, 91.3% (sd 19.1) showed reductions in Bwa/Boa, 86.7% (sd 18.4) reductions in Bwt/A, and 77.1% (sd 20.9) increases in Bin/A, whereas Bout/A remained stable. However, differences in the magnitude of these changes were observed at the segmental level within subjects. Pre-ETI, bronchial wall thickness was most strongly associated with neutrophil elastase. Post-ETI, this association weakened but persisted, while sialic acid emerged as an additional predictor of residual wall thickness. P. aeruginosa burden was also associated with wall thickness post-ETI but explained less of the variance than inflammatory and mucus markers.
Conclusions
ETI produces significant but variable improvements at the segmental level in bronchial dimensions. Persistent segmental heterogeneity suggests that local inflammation, mucus retention, and infection continue to shape residual structural lung disease. Automated segmental CT analysis may enable more individualized monitoring and management in the era of CFTR modulation.
Details
- Title: Subtitle
- Bronchial segmental heterogeneity of responsiveness to modulator therapy in cystic fibrosis: linking structural improvements on CT to Inflammation in Bronchoalveolar lavage fluid
- Creators
- Ieva AliukonyteSamantha L. DurfeySiddhartha G. KapnadakMary E. TeresiTahuanty PenaPunitkumar MakaniEleni-Rosalina AndrinopoulouRaul A. VillacresesJohn P. ClancyCharles R. EstherChad SteeleHettie M. JanssensPierluigi CietPradeep K. SinghDavid A. StoltzHarm A.W. M. Tiddens
- Resource Type
- Journal article
- Publication Details
- ERJ open research
- DOI
- 10.1183/23120541.00847-2026
- ISSN
- 2312-0541
- eISSN
- 2312-0541
- Language
- English
- Electronic publication date
- 09/10/2026
- Academic Unit
- Molecular Physiology and Biophysics; Pulmonary, Critical Care, and Occupational Medicine; Stead Family Department of Pediatrics; Internal Medicine
- Record Identifier
- 9985230929402771
Metrics
1 Record Views